Final height of Japanese patients with X-linked hypophosphatemic rickets: effect of vitamin D and phosphate therapy.
X-linked hypophosphatemic rickets (XLH) is one of the most common causes of rickets in infancy and childhood. Combination therapy of vitamin D and phosphate is generally used for patients with XLH. Effect of treatment of vitamin D and phosphate during childhood on final height of XLH has to be elucidated in Japanese. There have been only three Caucasian studies on final height of XLH with treatment since childhood. Purpose of this study is to report adult height and therapeutic effect of 22 Japanese participants (5 males, 17 females) with XLH who were treated with phosphate (33-200 mg/kg/day as phosphorus divided into 3 or 4 doses) and vitamin D (vitamin D2 or 1alpha-hydroxyvitamin D3) for more than five years and evaluate effect of the treatment on the final height retrospectively. Final height (FHt) for all participants was -1.69+/-11.11 SD. FHt (-1.69+/-1.11 SD) was significantly higher than height at the initiation of treatment (-2.38+/-0.88 SD) for all participants (P<0.01). In conclusion, combination therapy of vitamin D and phosphate improved final height of Japanese patients with XLH as is similar to previous Caucasian studies.
Miyamoto
J
J
Endocrinology, Metabolism and Genetics Unit, Tokyo Metropolitan Kiyose Children's Hospital, Japan.
Koto
S
S
Hasegawa
Y
Y
D000328:Adult; D001827:Body Height; D004872:Ergocalciferols / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use; D007015:Hypophosphatemia, Familial / Q000188:drug therapy / Q000503:physiopathology*; D007564:Japan; D008297:Male; D010710:Phosphates / Q000627:therapeutic use*; D012044:Regression Analysis; D014807:Vitamin D / Q000627:therapeutic use*
D004872:Ergocalciferols; D006887:Hydroxycholecalciferols; D010710:Phosphates; D014807:Vitamin D; C008088:alfacalcidol